KCKathleen M. Cain

Kathleen M. Cain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kathleen M. Cain has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing

    by Charles Eldrid, Ellie Hawke, Kathleen M. Cain, Kate Meeson, Joanne Watson, Reynard Spiess, Luke Johnston, William Smith, Matthew Russell, Robyn Hoare, et al.


  • Open Access

    From Discovery to Delivery: A Rapid and Targeted Proteomics Workflow for Monitoring Chinese Hamster Ovary Biomanufacturing

    by Charles Eldrid, Ellie Hawke, Kathleen M. Cain, Kate Meeson, Joanne Watson, Reynard Spiess, William Smith, Matthew Russell, Robyn Hoare, John Raven, et al.

    Chinese hamster ovary (CHO) cells are the industrial workhorse for manufacturing biopharmaceuticals, including monoclonal antibodies. CHO cell line development requires a more data-driven approach for the accelerated identification of hyper-productive cell lines. Traditional methods, which rely on time-consuming hierarchical screening, often fail to elucidate the underlying cellular mechanisms driving optimal bioreactor performance. Big data analytics, coupled with advancements in ‘omics’ technologies, are revolutionizing the study of industrial cell lines. However, translating this knowledge into practical methods widely utilized in industrial biomanufacturing remains a significant challenge. This study leverages discovery proteomics to characterize dynamic changes within the CHO cell proteome during a 14 day fed-batch bioreactor cultivation. Utilizing a global untargeted proteomics workflow, we identify 3358 proteins, using a ZenoTOF 7600 and a Cyclic IMS QToF. By mapping relative abundances to key cellular processes, eight protein targets were selected as potential biomarkers. To bridge the gap between discovery and industrial applications, we translated these findings into a rapid 15 minute targeted triple quadrupole (MRM) assay. This approach demonstrates the potential of repurposing discovery proteomics for targeted biomarker identification in biotherapeutic production. By monitoring these biomarkers we can potentially streamline the screening of biomanufacturing cell lines and culture conditions, ultimately accelerating biotherapeutic development.

  • Open Access

    Development and translation of a method of clinical utility for LC-MS/MS analysis to detect SARS-CoV-2 antigens from ONP swabs and saliva

    by N Leigh Anderson, Alistair Bailey, Perdita Barran, Philip Brownbridge, Kathleen Cain, Rachel S Carling, Rainer Cramer, R Neil Dalton, Matthew E Daly, Kayleigh Davis, et al.

    During the COVID-19 pandemic, development of diagnostic tests was vital to chart the course and to reduce the impact of the infection. Continued testing and surveillance of vaccine escape will continue for years to come which presents an opportunity to integrate such testing into clinical biochemistry laboratories that form part of integrated healthcare testing. Here we describe a protocol for a targeted mass spectrometry based proteomic assay (COVIDCAP) developed to detect SARS-CoV-2 peptides from oro-nasopharyngeal swabs (ONP) and saliva. This uses novel SISCAPA antibodies bound to magnetic beads and subsequent analysis of captured and purified SARS-CoV-2 nucleocapsid (NCAP) peptides. The method involves immediate deactivation of the sample using an ethanolic solution. This simultaneously inactivates the virus and denatures viral proteins at sampling in contrast to the approach for RT-PCR testing, with benefits for the assay as well as for downstream processing. A plate-based preparation of the samples involving acetone precipitation followed by a short tryptic digestion and subsequent immunocapture allows LC-MS detection and quantification of peptides from the NCAP protein, in a 3-minute inject-to-inject assay with an LOD of 20 attomoles from starting sample. For 576 ONP swab samples taken as exemplars here, the sensitivity and specificity of this analysis is shown to be 97.0% and 96.6% respectively.